1. Implantable continuous-flow right ventricular assist device: lessons learned in the development of a cleveland clinic device.
- Author
-
Fukamachi K, Shiose A, Massiello AL, Horvath DJ, Golding LA, Lee S, and Starling RC
- Subjects
- Animals, Anticoagulants therapeutic use, Disease Models, Animal, Equipment Safety, Female, Heart Failure mortality, Heart Failure physiopathology, Heart Failure surgery, Humans, Male, Needs Assessment, Ohio, Prognosis, Prosthesis Implantation, Pulsatile Flow physiology, Risk Assessment, Survival Analysis, Thromboembolism drug therapy, Thromboembolism physiopathology, Ventricular Dysfunction, Right physiopathology, Equipment Design, Equipment Failure, Heart-Assist Devices, Ventricular Dysfunction, Right surgery
- Abstract
Although the need for right ventricular assist device (RVAD) support for right ventricular failure after the implantation of a continuous-flow left ventricular assist device has decreased, right ventricular failure still occurs in as many as 44% of patients after continuous-flow left ventricular assist device insertion. Cleveland Clinic's DexAide continuous-flow RVAD was implanted in 34 calves during the course of its development. This review discusses lessons learned in the design and development of an implantable continuous-flow RVAD that are drawn from the results of these in vivo studies, our clinical experience with RVAD support, and a review of previously published reports on clinical RVAD use., (Copyright © 2012 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF